Bisfosfonatassocieret osteonekrose i kaeberne hos patienter med myelomatose

Thomas Lund; Henrik Gregersen; Annette Vangsted; Peter Marker; Niels Abildgaard

Bisfosfonatassocieret osteonekrose i kaeberne hos patienter med myelomatose

Translated title of the contribution: Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma

Thomas Lund, Henrik Gregersen, Annette Vangsted, Peter Marker, Niels Abildgaard

5 Citations (Scopus)

Abstract

Bisphosphonate-associated osteonecrosis of the jaw (BON) is mainly observed in patients with multiple myeloma, and to a lesser extent in breast and prostate cancer patients receiving intravenous treatment with potent bisphosphonates. The incidence of BON increases with the duration of bisphosphonate therapy and with the potency of the used bisphosphonate. BON usually develops after tooth extraction or other oral surgery, and has proven difficult to treat. Optimal dental hygiene should be ensured prior to treatment initiation where possible, and once bisphosphonate treatment is instituted, oral surgery should be avoided if possible.
Udgivelsesdato: 2009-Jan

Translated title of the contribution	Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma
Original language	Danish
Journal	Ugeskrift for læger
Volume	171
Issue number	1-2
Pages (from-to)	50-2
Number of pages	3
ISSN	0041-5782
Publication status	Published - 2009

Cite this

@article{33ee7d60746911df928f000ea68e967b,

title = "Bisfosfonatassocieret osteonekrose i kaeberne hos patienter med myelomatose",

abstract = "Bisphosphonate-associated osteonecrosis of the jaw (BON) is mainly observed in patients with multiple myeloma, and to a lesser extent in breast and prostate cancer patients receiving intravenous treatment with potent bisphosphonates. The incidence of BON increases with the duration of bisphosphonate therapy and with the potency of the used bisphosphonate. BON usually develops after tooth extraction or other oral surgery, and has proven difficult to treat. Optimal dental hygiene should be ensured prior to treatment initiation where possible, and once bisphosphonate treatment is instituted, oral surgery should be avoided if possible. Udgivelsesdato: 2009-Jan",

author = "Thomas Lund and Henrik Gregersen and Annette Vangsted and Peter Marker and Niels Abildgaard",

note = "Keywords: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw; Multiple Myeloma; Oral Hygiene; Osteonecrosis; Risk Factors",

year = "2009",

language = "Dansk",

volume = "171",

pages = "50--2",

journal = "Ugeskrift for l{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "1-2",

}

TY - JOUR

T1 - Bisfosfonatassocieret osteonekrose i kaeberne hos patienter med myelomatose

AU - Lund, Thomas

AU - Gregersen, Henrik

AU - Vangsted, Annette

AU - Marker, Peter

AU - Abildgaard, Niels

N1 - Keywords: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw; Multiple Myeloma; Oral Hygiene; Osteonecrosis; Risk Factors

PY - 2009

Y1 - 2009

N2 - Bisphosphonate-associated osteonecrosis of the jaw (BON) is mainly observed in patients with multiple myeloma, and to a lesser extent in breast and prostate cancer patients receiving intravenous treatment with potent bisphosphonates. The incidence of BON increases with the duration of bisphosphonate therapy and with the potency of the used bisphosphonate. BON usually develops after tooth extraction or other oral surgery, and has proven difficult to treat. Optimal dental hygiene should be ensured prior to treatment initiation where possible, and once bisphosphonate treatment is instituted, oral surgery should be avoided if possible. Udgivelsesdato: 2009-Jan

AB - Bisphosphonate-associated osteonecrosis of the jaw (BON) is mainly observed in patients with multiple myeloma, and to a lesser extent in breast and prostate cancer patients receiving intravenous treatment with potent bisphosphonates. The incidence of BON increases with the duration of bisphosphonate therapy and with the potency of the used bisphosphonate. BON usually develops after tooth extraction or other oral surgery, and has proven difficult to treat. Optimal dental hygiene should be ensured prior to treatment initiation where possible, and once bisphosphonate treatment is instituted, oral surgery should be avoided if possible. Udgivelsesdato: 2009-Jan

M3 - Tidsskriftartikel

C2 - 19128568

SN - 0041-5782

VL - 171

SP - 50

EP - 52

JO - Ugeskrift for læger

JF - Ugeskrift for læger

IS - 1-2

ER -